Page last updated: 2024-08-21

canrenone and Hyperpotassemia

canrenone has been researched along with Hyperpotassemia in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	1 (33.33)	24.3611
2020's	1 (33.33)	2.80

Authors

Authors	Studies
Bolignano, D; Chung, EY; Natale, P; Navaneethan, SD; Palmer, SC; Ruospo, M; Strippoli, GF	1
Agostoni, P; Boccanelli, A	1
Fumeaux, Z; Mach, F; Martin, PY; Perneger, T; Rossier, M; Saudan, P; Schnetzler, B; Stoermann, C	1

Reviews

1 review(s) available for canrenone and Hyperpotassemia

Article	Year
Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease. The Cochrane database of systematic reviews, 2020, 10-27, Volume: 10 Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bias; Calcium Channel Blockers; Canrenone; Disease Progression; Eplerenone; Humans; Hyperkalemia; Kidney Failure, Chronic; Mineralocorticoid Receptor Antagonists; Naphthyridines; Proteinuria; Randomized Controlled Trials as Topic; Spironolactone	2020

Article

Year

Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease.

The Cochrane database of systematic reviews, 2020, 10-27, Volume: 10

Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bias; Calcium Channel Blockers; Canrenone; Disease Progression; Eplerenone; Humans; Hyperkalemia; Kidney Failure, Chronic; Mineralocorticoid Receptor Antagonists; Naphthyridines; Proteinuria; Randomized Controlled Trials as Topic; Spironolactone

2020

Trials

1 trial(s) available for canrenone and Hyperpotassemia

Article	Year
Safety of low-dose spironolactone administration in chronic haemodialysis patients. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2003, Volume: 18, Issue:11 Topics: Adult; Aged; Aldosterone; Canrenone; Humans; Hyperkalemia; Kidney Failure, Chronic; Middle Aged; Mineralocorticoid Receptor Antagonists; Potassium; Renal Dialysis; Spironolactone	2003

Article

Year

Safety of low-dose spironolactone administration in chronic haemodialysis patients.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2003, Volume: 18, Issue:11

Topics: Adult; Aged; Aldosterone; Canrenone; Humans; Hyperkalemia; Kidney Failure, Chronic; Middle Aged; Mineralocorticoid Receptor Antagonists; Potassium; Renal Dialysis; Spironolactone

2003

Other Studies

1 other study(ies) available for canrenone and Hyperpotassemia

Article	Year
[The EMPHASIS-HF study]. Giornale italiano di cardiologia (2006), 2011, Volume: 12, Issue:5 Topics: Aldosterone; Biomarkers; Canrenone; Cause of Death; Double-Blind Method; Early Termination of Clinical Trials; Eplerenone; Female; Heart Failure; Hospitalization; Humans; Hyperkalemia; Male; Mineralocorticoid Receptor Antagonists; Models, Cardiovascular; Molecular Structure; Multicenter Studies as Topic; Myocardial Infarction; Patient Selection; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Research Design; Risk; Spironolactone	2011

Article

Year

[The EMPHASIS-HF study].

Giornale italiano di cardiologia (2006), 2011, Volume: 12, Issue:5

Topics: Aldosterone; Biomarkers; Canrenone; Cause of Death; Double-Blind Method; Early Termination of Clinical Trials; Eplerenone; Female; Heart Failure; Hospitalization; Humans; Hyperkalemia; Male; Mineralocorticoid Receptor Antagonists; Models, Cardiovascular; Molecular Structure; Multicenter Studies as Topic; Myocardial Infarction; Patient Selection; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Research Design; Risk; Spironolactone

2011